Font size:
Print
Nafithromycin and India’s Drug Development
Context:
India, long hailed as the “pharmacy of the world” for its affordable generic drugs and vaccines, has made a groundbreaking foray into novel drug development.
More on News
- Nafithromycin, expected to launch under the brand name Miqnaf in 2025, represents a significant milestone.
- Developed by Wockhardt with support from the Biotechnology Industry Research Assistance Council (BIRAC), it is India’s first indigenously developed novel antibiotic for combating resistant infections.
- Targeting Community-Acquired Bacterial Pneumonia (CABP), Nafithromycin addresses the escalating global health crisis of antimicrobial resistance (AMR) and underscores India’s potential in pharmaceutical innovation.
A Timely Innovation:
- The emergence of Nafithromycin is critical given the current global health landscape.
- Pneumonia remains one of the leading causes of mortality worldwide, with the problem exacerbated by AMR, which renders many treatments ineffective.
- The absence of new antibiotic classes since the 1980s has left healthcare systems reliant on outdated drugs that struggle to combat evolving pathogens.
- Nafithromycin offers a beacon of hope, demonstrating how targeted public-private collaboration can overcome market failures in this vital area.
The Urgent Need for New Antibiotics:
- Often referred to as the “silent pandemic,” AMR threatens to undo decades of medical progress and is projected to cause 10 million deaths annually by 2050.
- Pneumonia, a major contributor to this toll, disproportionately affects low- and middle-income countries.
- India, for instance, accounts for 23% of global pneumonia deaths and reports an estimated 4 million CABP cases annually.
- The pharmaceutical industry’s retreat from antibiotic development, due to unappealing economic models involving short treatment cycles, restricted usage, and pricing pressures, has compounded the crisis.
- Investment in antibiotic research has declined, leaving innovation largely to underfunded smaller firms and academic institutions.
- Even when new antibiotics emerge, they are often derivatives of existing classes with limited efficacy against resistant pathogens.
- Nafithromycin breaks this trend by offering a novel solution to a critical global challenge.
The Science Behind Nafithromycin:
- Nafithromycin’s clinical and practical advantages position it as a valuable tool for practitioners and patients.
- It is ten times more potent than azithromycin and achieves comparable outcomes within a shorter three-day regimen, improving patient compliance and outcomes.
- Its ability to target both typical and atypical pathogens, including drug-resistant strains, enhances its utility as a first-line treatment for CABP.
- Nafithromycin has minimal gastrointestinal side effects and negligible drug interactions, making it a safer option for a broad patient demographic.
A Model of Public-Private Collaboration:
- The development of Nafithromycin exemplifies the importance of public-private partnerships (PPPs) in addressing healthcare challenges.
- The United Nations General Assembly (UNGA) has recognised the role of PPPs in combating AMR, with initiatives like CARB-X and GARDP paving the way globally.
- In India, PPPs are central to the National Health Mission and critical to advancing the biopharma sector.
- BIRAC, a public sector enterprise under the Department of Biotechnology (DBT), provided INR 8 crore (~$945,000) to support Phase III clinical trials for Nafithromycin.
- Other notable breakthroughs supported by BIRAC include CERVAVAC, a quadrivalent HPV vaccine developed with the Serum Institute of India and the Bill & Melinda Gates Foundation, and ZyCoV-D, the world’s first DNA-based COVID-19 vaccine developed by Zydus Cadila.
What Nafithromycin Represents for India:
- Developing and commercialising antibiotics typically requires 10–15 years; Nafithromycin’s 14-year journey underscores the challenges of such efforts.
- Large pharmaceutical companies have largely abandoned antibiotic development due to low returns on investment, leaving smaller firms to fill the void despite limited resources.
- Policies like BioE3 (Biotechnology for Economy, Environment, and Employment) and Bio-RIDE (Biotechnology – Research, Innovation, and Entrepreneurship Development) aim to attract investments worth INR 10,000 crore (~$11.8 billion) to the biomanufacturing sector.
India’s bioeconomy has already grown from $10 billion to $151 billion over the past decade, supported by a thriving start-up ecosystem and a young, skilled workforce.
